Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Companies
Neonc Technologies

companiesCompany

NT

Neonc Technologies

Neonc Technologies is a United States-based biotechnology company running 3 late-stage cancer trials of NEO212 Oral and NEO100 in glioma & glioblastoma, cervical cancer and colorectal cancer.

Also called: Neonc Technologies, Inc.

Overview Connected10

Overview

Neonc Technologies, based in Calabasas, the United States, is a biotechnology company listed as NASDAQ: NTHI. NeOnc develops drug delivery therapeutics for central nervous system diseases, using a perillyl-alcohol-based platform intended to transport therapeutics across the blood-brain barrier. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing NEO212 Oral and NEO100 in glioma & glioblastoma, cervical cancer, colorectal cancer, oesophageal cancer and gastric & gastro-oesophageal junction cancer. The largest, NCT06047379 (Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis), plans to enrol 134 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

Headquarters

Calabasas, US

Type

Biotech · NASDAQ: NTHI

Stage

Public

Website

Connected

Similar pages

Journal
Tumour virus research
Shares Merkel cell carcinoma, Cervical cancer, Head and neck squamous cell carcinoma.
Trial
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Shares Merkel cell carcinoma, Head and neck squamous cell carcinoma, Melanoma.
Person
Dirk Schadendorf
Shares Merkel cell carcinoma, Melanoma.
Trial
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Shares Merkel cell carcinoma, Melanoma.
Trial
CheckMate 358
Shares Merkel cell carcinoma, Cervical cancer.
Term
Why nobody knows how many skin cancers there are: the counting rule behind every figure
Shares Merkel cell carcinoma, Melanoma.
Person
Reinhard Dummer
Shares Merkel cell carcinoma, Melanoma.
Person
Shailender Bhatia
Shares Merkel cell carcinoma, Melanoma.

cancers

Cervical cancer Colorectal cancer Gastric & gastro-oesophageal junction cancer Glioma & glioblastoma Head and neck squamous cell carcinoma Melanoma Merkel cell carcinoma Oesophageal cancer

trials

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

ProvenanceLast edited 2026-09-17 · Jude Gomila · Reverse links for orphaned trials · diff · file

Sources & links

Official website
ClinicalTrials.gov: trials led by Neonc Technologies

Data

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Cancers

Glioma & glioblastoma
Cervical cancer
Colorectal cancer
Oesophageal cancer
Gastric & gastro-oesophageal junction cancer
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma

Trials

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

Not yet reviewedSee the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Neonc Technologies

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/companies/neonc-technologies/)
All companies as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id neonc-technologies.

WebMCP tools registered on this page: onco_search, onco_get_entity.